Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.55 |
| ▸ | TACR2 | P21452 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623293 | 0.85 | TACR3 (0.58) | TACR3TACR2TACR1CYP3A4CYP2D6 | |
| SCHEMBL623693 | 0.82 | TACR3 (0.57) | TACR3TACR2TACR1CYP3A4CYP2D6 | |
| SCHEMBL624166 | 0.78 | TACR3 (0.38) | TACR3CYP2C9MEN1KMT2A | |
| SCHEMBL623777 | 0.76 | P2RY12 (0.46) | — | |
| SCHEMBL623147 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2A | |
| SCHEMBL623166 | 0.75 | KMT2A (0.45) | TACR3MEN1KMT2A | |
| SCHEMBL623267 | 0.75 | KCNK3 (0.43) | MEN1KMT2A | |
| SCHEMBL623690 | 0.73 | POLB (0.51) | MEN1KMT2A | |
| SCHEMBL623692 | 0.73 | HRH4 (0.47) | — | |
| SCHEMBL623239 | 0.73 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | claimed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | claimed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | TACR3 218/4885TACR2 528/4885TACR1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.